타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Cyclosporine | Selinexor | mycophenolate mofetil | Mabthera | tacrolimus |
Overview Company | Amsterdam Molecular Therapeutics | Qilu Pharmaceutical Co., Ltd. | Amsterdam Molecular Therapeutics | Roche / Genentech | Tolera Therapeutics, Inc |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia | NKTCL | Chronic Myeloproliferative Disorders; Leukemia | Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma | Leukemia; Lymphoma |
Overview Phase | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | ACTIVE | RECRUITING | ACTIVE | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational | Investigational | Investigational | Investigational |
MoA Mechanism | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling | Targeting the nuclear export receptor | Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite | bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma | Tacrolimus binds to an intracellular protein, FKBP-12 |
MoA Biomarker | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat | biomarker after CRS+HIPEC and a therapeutic target | CD20+ B cell levels rapidly declining to extremely low | CD20-positive, low | biomarkers of inflammation, and histopathological findings |
Clinical Program phase | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | Mouse | — | — | — | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 5개 · 임상 갱신 필요 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Cyclosporine | Selinexor | mycophenolate mofetil | Mabthera | tacrolimus |
Overview Company | Amsterdam Molecular Therapeutics | Qilu Pharmaceutical Co., Ltd. | Amsterdam Molecular Therapeutics | Roche / Genentech | Tolera Therapeutics, Inc |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | FRα | FRα | FRα | FRα | FRα |
Overview Indication | Chronic Myeloproliferative Disorders; Leukemia | NKTCL | Chronic Myeloproliferative Disorders; Leukemia | Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma | Leukemia; Lymphoma |
Overview Phase | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | ACTIVE | RECRUITING | ACTIVE | ACTIVE | ACTIVE |
Overview Content status | Limited Data | Limited Data | Limited Data | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging | Development Signal · Emerging |
Overview Approval status | Investigational | Investigational | Investigational | Investigational | Investigational |
MoA Mechanism | target interactions (TNF, NF‑κB, STAT3, IL-1β, AKT1, IL-6, Src) and pathways (IL-17, PI3K-Akt, TNF signaling | Targeting the nuclear export receptor | Mycophenolate mofetil (MMF) is absorbed following oral administration and hydrolyzed to mycophenolic acid (MPA), the active metabolite | bispecific antibodies to enhance macrophage-mediated cytotoxicity of B-cell lymphoma | Tacrolimus binds to an intracellular protein, FKBP-12 |
MoA Biomarker | biomarker data support an endotype-driven approach: higher total immunoglobulin E (IgE) is generally associat | biomarker after CRS+HIPEC and a therapeutic target | CD20+ B cell levels rapidly declining to extremely low | CD20-positive, low | biomarkers of inflammation, and histopathological findings |
Clinical Program phase | PHASE_3 | PHASE_2 | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | Mouse | — | — | — | — |
추천 비교
추천 비교